April 22, 2020

Jacob Chacko, M.D.
President and Chief Executive Officer
Oric Pharmaceuticals, Inc.
240 E. Grand Ave, 2nd Floor
South San Francisco, CA 94080

       Re: Oric Pharmaceuticals, Inc.
           Amendment No. 1 to Registration Statement on Form S-1
           Filed April 20, 2020
           File No. 333-236792

Dear Dr. Chacko:

      We have reviewed your amended registration statement and have the
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
circumstances or do not believe an amendment is appropriate, please tell us why
in your

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Amendment No. 1 to Registration Statement on Form S-1 filed April 20, 2020

Risk Factors
Our amended and restated bylaws that will become effective upon the closing of
this offering
provide..., page 79

1.     We note that your forum selection provision identifies a state court
located within the
       State of Delaware (or, if the Court of Chancery does not have
jurisdiction, another State
       court in Delaware or the federal district court for the District of
Delaware) as the exclusive
       forum for certain litigation, including any "derivative action." Please
disclose whether
       this provision applies to actions arising under the Exchange Act. If
this provision does not
       apply to actions arising under the Exchange Act, please also ensure that
the exclusive
       forum provision in the governing documents states this clearly, or tell
us how you will
       inform investors in future filings that the provision does not apply to
any actions arising
 Jacob Chacko, M.D.
Oric Pharmaceuticals, Inc.
April 22, 2020
Page 2
      under the Exchange Act. We also note that your forum selection provision
includes an
      exclusive federal forum provision for Securities Act claims. Please state
that there is
      uncertainty as to whether a court would enforce such provision. In that
regard, we note
      that Section 22 of the Securities Act creates concurrent jurisdiction for
federal and state
      courts over all suits brought to enforce any duty or liability created by
the Securities Act
      or the rules and regulations thereunder.
Report of Independent Registered Public Accounting Firm, page F-2

2.    Please have your auditors remove the restrictive language from their
report and consent
      and sign them in the filing for which you request effectiveness.

       You may contact Ibolya Ignat at 202-551-3636 or Kevin Vaughn at
202-551-3494 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jeffrey Gabor at 202-551-2544 or Celeste Murphy at 202-551-3257 with
any other

FirstName LastNameJacob Chacko, M.D.
                                                             Division of
Corporation Finance
Comapany NameOric Pharmaceuticals, Inc.
                                                             Office of Life
April 22, 2020 Page 2
cc:       Melissa Rick, Esq.
FirstName LastName